RxDoctor Payments Data

Navin Kaini, MD

Pulmonary Disease · Elizabethtown, KYNPI 1689821829

Payments from drug & device makers

$10,899in general payments, 2019–2025

Across 228 payments — averaging $47.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$7K
  • Insmed, Inc.$515
  • GSK$400
  • Actelion Pharmaceuticals US, Inc.$393
  • Boehringer Ingelheim$266
  • Grifols USA, LLC$248
  • plus $2K from 36 others

What the payments were for

  • Travel & lodging$9859%
  • Food & beverage$3,68434%
  • Education$6,23157%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,899 in reported general payments places this provider in the 70th percentile of 226 pulmonary disease providers in Kentucky.

See all pulmonary disease providers in Kentucky

Medicare billing

Part B allowed, 2024
$312,119
Medicare patients
807
Services billed
3,009

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate28$334,267
ArikayceAmikacin Liposomal/Neb.Accessr14$203,870
GlassiaAlpha-1-Proteinase Inhibitor16$163,955
Trelegy ElliptaFluticasone/Umeclidin/Vilanter194$146,281
Spiriva RespimatTiotropium Bromide149$97,659
XolairOmalizumab23$91,527
Breztri AerosphereBudesonide/Glycopyr/Formoterol84$73,193
Stiolto RespimatTiotropium Br/Olodaterol Hcl120$67,133
NucalaMepolizumab12$44,266
Breo ElliptaFluticasone/Vilanterol52$24,251
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr28$16,210
Advair HfaFluticasone Propion/Salmeterol25$11,838
Arnuity ElliptaFluticasone Furoate29$10,866
Albuterol Sulfate HfaAlbuterol Sulfate337$9,830
Spiriva HandihalerTiotropium Bromide15$8,550

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat$266$499,059297 claims
GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta$400$249,535337 claims
Insmed, Inc.Arikayce$515$203,87014 claims
Takeda Pharmaceuticals U.S.A., Inc.Glassia$52$163,95516 claims
AstraZenecaBreztri Aerosphere, Symbicort, Pulmicort Flexhaler$223$80,740112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 226 pulmonary disease providers in Kentucky.

Other pulmonary disease in Elizabethtown

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →